Rapid functional screening of effective siRNAs against Plk1 and its growth inhibitory effects in laryngeal carcinoma cells

BMB Reports

Volumn 43, Issue 12, 2010, Pages 818-823

  Lan, Huan ^a   Zhu, Jiang ^a   Ai, Qing ^a   Yang, Zhengmei ^a   Ji, Ying ^a   Hong, Suling ^a   Song, Fangzhou ^a   Bu, Youquan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Laryngeal carcinoma; Plk1; RNA silencing

Indexed keywords

CELL CYCLE PROTEIN; ONCOPROTEIN; POLO LIKE KINASE 1; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CARCINOMA; CELL PROLIFERATION; DRUG ANTAGONISM; GENETICS; HUMAN; LARYNX TUMOR; METABOLISM; MITOSIS; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LARYNGEAL NEOPLASMS; MITOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 78650713406     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2010.43.12.818     Document Type: Article

References (26)

1. Glover, D.M., Hagan, I.M. and Tavares, A.A. (1998) Polo-like kinases: a team that plays throughout mitosis. Genes. Dev. 12, 3777-3787.
2. Golsteyn, R.M., Schultz, S.J., Bartek, J., Ziemiecki, A., Ried, T. and Nigg, E.A. (1994) Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J. Cell Sci. 107, 1509-1517.
3. Strebhardt, K. and Ullrich, A. (2006) Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6, 321-330.
4. Chopra, P., Sethi, G., Dastidar, S.G. and Ray, A. (2010) Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert. Opin. Investig. Drugs 19, 27-43.
5. Degenhardt, Y. and Lampkin, T. (2010) Targeting Pololike kinase in cancer therapy. Clin. Cancer Res. 16, 384-389.
6. Takai, N., Hamanaka, R., Yoshimatsu, J. and Miyakawa, I. (2005) Polo-like kinases (Plks) and cancer. Oncogene. 24, 287-291.
7. Knecht, R., Elez R., Oechler, M., Solbach, C., von Ilberg, C. and Strebhardt, K. (1999) Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59, 2794-2797.
8. Spänkuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., and Strebhardt, K. (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 94, 1863-1877.
9. Rizki, A., Mott, J.D. and Bissell, M.J. (2007) Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res. 67, 11106-11110.
10. Liu, X. and Erikson, R.L. (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 5789-5794.
11. Reagan-Shaw, S. and Ahmad, N. (2005) Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J. 19, 611-613.
12. Liu, X., Lei, M. and Erikson, R.L. (2006) Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell Biol. 26, 2093-2108.
13. Bumcrot, D., Manoharan, M., Koteliansky, V. and Sah, D.W. (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2, 711-719.
14. Tiemann, K. and Rossi, J.J. (2009) RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol. Med. 1, 142-151.
15. Bu, Y., Yang, Z., Li, Q. and Song, F. (2008) Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells. Oncology 74, 198-206.
16. Marioni, G., Marchese-Ragona, R., Cartei, G., Marchese, F. and Staffieri, A. (2006) Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat. Rev. 32, 504-515.
17. Papadas, T.A., Alexopoulos, E.C., Mallis, A., Jelastopulu, E., Mastronikolis, N.S. and Goumas, P. (2010) Survival after laryngectomy: a review of 133 patients with laryngeal carcinoma. Eur. Arch. Otorhinolaryngol. 267, 1095-1101.
18. Juan, G., Traganos, F., James, W.M., Ray, J.M., Roberge, M., Sauve, D.M., Anderson, H. and Darzynkiewicz, Z. (1998) Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 32, 71-77.
19. Tilesi, F., Fradiani, P., Socci, V., Willems, D. and Ascenzioni, F. (2009) Design and validation of siRNAs and shRNAs. Curr. Opin. Mol. Ther. 11, 156-164.
20. Huesken, D., Lange, J., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J., Meloon, B., Engel, S., Rosenberg, A., Cohen, D., Labow, M., Reinhardt, M., Natt, F. and Hall, J. (2005) Design of a genome-wide siRNA library using an artificial neural network. Nat. Biotechnol. 23, 995-1001.
21. Hung, C.F., Lu, K.C., Cheng, T.L., Wu, R.H., Huang, L.Y., Teng, C.F. and Chang, W.T. (2006) A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells. Biochem. Biophys. Res. Commun. 346, 707-720.
22. Luo, Q., Kang, Q., Song, W.X., Luu, H.H., Luo, X., An, N., Luo, J., Deng, Z.L., Jiang, W., Yin, H., Chen, J., Sharff, K.A., Tang, N., Bennett, E., Haydon, R.C. and He, T.C. (2007) Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing. Gene 395, 160-169.
23. Liu, X. and Erikson, R.L. (2002) Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc. Natl. Acad. Sci. U.S.A. 99, 8672-8676.
24. Roshak, A.K., Capper, E.A., Imburgia, C., Fornwald, J., Scott, G. and Marshall, L.A. (2000) The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 12, 405-411.
25. Yamada, S., Ohira, M., Horie, H., Ando, K., Takayasu, H., Suzuki, Y., Sugano, S., Hirata, T., Goto, T., Matsunaga, T., Hiyama, E., Hayashi, Y., Ando, H., Suita, S., Kaneko, M., Sasaki, F., Hashizume, K., Ohnuma, N. and Nakagawara, A. (2004) Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 23, 5901-5911.
26. Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.